Vorinostat is a histone deacetylase (HDAC) inhibitor used for the treatment of cutaneous manifestations in patients with progressive, persistent, or recurrent cutaneous T‐ cell lymphoma (CTCL) following prior systemic therapies [52]. The gene discussed is HDAC9; the disease is primary cutaneous T-cell non-Hodgkin lymphoma.